The estimated Net Worth of Richard J Rodgers is at least $224 Tisíc dollars as of 12 June 2024. Mr. Rodgers owns over 6,670 units of Ardelyx Inc stock worth over $62,401 and over the last 10 years he sold ARDX stock worth over $0. In addition, he makes $161,985 as Independent Director at Ardelyx Inc.
Richard has made over 2 trades of the Ardelyx Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 6,670 units of ARDX stock worth $39,753 on 12 June 2024.
The largest trade he's ever made was exercising 6,670 units of Ardelyx Inc stock on 12 June 2024 worth over $39,753. On average, Richard trades about 455 units every 10 days since 2014. As of 12 June 2024 he still owns at least 10,470 units of Ardelyx Inc stock.
You can see the complete history of Mr. Rodgers stock trades at the bottom of the page.
Richard J. Rodgers is Independent Director of the Company. From March 2010 until August 2013, Mr. Rodgers was co-founder, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Tesaro, Inc. (Nasdaq: TSRO). Mr. Rodgers previously served as the Chief Financial Officer of Abraxis BioScience, Inc., a biotechnology company, from June 2009 to February 2010. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc., a biopharmaceutical company, from 2004 until its acquisition by Eisai Co. Ltd., a pharmaceutical company, in January 2008. Mr. Rodgers has held finance and accounting positions at several private and public companies, including Arthur Anderson & Co. Mr. Rodgers currently serves as a director of Rexahn Pharmaceuticals, Inc. (NYSE: RNN). Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State University and his M.B.A. in Finance from the University of Minnesota, Carlson School of Business.
As the Independent Director of Ardelyx Inc, the total compensation of Richard Rodgers at Ardelyx Inc is $161,985. There are 8 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Richard Rodgers is 53, he's been the Independent Director of Ardelyx Inc since 2014. There are 16 older and 3 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: